Radiologic response (RR) by MRI in patients (pts) with muscle-invasive urothelial cancer (MIUC) undergoing neoadjuvant chemotherapy

被引：0
|
作者：
Qu, Angela Q.
Choueiri, Toni K.
Jacobus, Susanna J.
Rosenberg, Jonathan E.
Ramaiya, Nikhil H.
Krajewski, Katherine Maragaret
机构：
[1] Dana Farber Canc Inst, Boston, MA 02115 USA
[2] Harvard Univ, Brigham & Womens Hosp, Sch Med, Lank Ctr Genitourinary Oncol,Dana Farber Canc Ins, Boston, MA 02115 USA
[3] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2013年 / 31卷 / 06期
关键词：
D O I：
10.1200/jco.2013.31.6_suppl.283
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
283
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Adjuvant chemotherapy for residual disease after neoadjuvant chemotherapy for muscle invasive urothelial cancer (MIUC)
    Harshman, Lauren Christine
    Werner, Lillian
    Wong, Yu-Ning
    Yu, Evan Y.
    Alva, Ajjai Shivaram
    Crabb, Simon J.
    Powles, Thomas
    Rosenberg, Jonathan E.
    Baniel, Jack
    Vaishampayan, Ulka N.
    Berthold, Dominik R.
    Ladoire, Sylvain
    Hussain, Syed A.
    Milowsky, Matthew I.
    Agarwal, Neeraj
    Necchi, Andrea
    Pal, Sumanta Kumar
    Recine, Federica
    Bellmunt, Joaquim
    Galsky, Matt D.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [2] Avelumab (A) as neoadjuvant therapy in patients (pts) with muscle-invasive urothelial carcinoma (MIUC): Survival data of AURA trial, Oncodistinct 004
    Blanc, Jeremy
    Carnot, Aurelien
    Barthelemy, Philippe
    Casert, Vinciane
    Staudacher, Lionel
    Van den Brande, Jan
    Sautois, Brieuc
    Vanhaudenarde, Vincent
    Seront, Emmanuel
    Debien, Veronique
    Ameye, Lieveke
    Kotecki, Nuria
    Fantoni, Jean Christophe
    Tricard, Thibault
    Roumeguere, Thierry Andre
    Awada, Ahmad
    Chanza, Nieves Martinez
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [3] Using radiologic response to predict prognosis in patients with muscle-invasive bladder cancer undergoing carboplatin-based neoadjuvant chemotherapy
    Hatakeyama, Shingo
    Yamamoto, Hayato
    Okamoto, Akiko
    Imai, Atsushi
    Yoneyama, Takahiro
    Hashimoto, Yasuhiro
    Koie, Takuya
    Ohyama, Chikara
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (04)
  • [4] A phase II multicenter study of neoadjuvant dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin (ddMVAC) chemotherapy with pegfilgrastim support in patients (pts) muscle-invasive urothelial cancer (MIUC): Safety, pathologic, radiologic, and molecular correlates
    Choueiri, Toni K.
    Jacobus, Susanna J.
    Qu, Angela Q.
    Sweeney, Christopher
    Appleman, Leonard Joseph
    Tretter, Christopher P. G.
    Bubley, Glenn J.
    Elfiky, Aymen
    Park, Rachel
    Stack, Edward C.
    Signoretti, Sabina
    Walsh, Meghara K.
    Steele, Graeme
    Hirsch, Michelle S.
    Krajewski, Katherine Maragaret
    Taplin, Mary-Ellen
    Rosenberg, Jonathan E.
    Ross, Robert W.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (06)
  • [5] Real-world (RW) characteristics and outcomes in patients (pts) with muscle-invasive urothelial carcinoma (MIUC) treated with adjuvant nivolumab (NIVO) with or without neoadjuvant chemotherapy (NAC)
    Ebrahimi, H.
    Barragan-Carrillo, R.
    John, W. S.
    Lucht, S.
    Miller, T.
    Pathak, P.
    Bland, E.
    Gordon, S.
    Laney, J.
    Klink, A. J.
    Feinberg, B. A.
    Singh, N.
    Alonso, C.
    Patel, M.
    Rosenblatt, L. C.
    Yin, X.
    Chehrazi-Raffle, A.
    ANNALS OF ONCOLOGY, 2024, 35 : S1152 - S1152
  • [6] Patterns and potential benefit of adjuvant chemotherapy for residual muscle invasive disease after neoadjuvant chemotherapy for muscle invasive urothelial cancer (MIUC)
    Harshman, L.
    Werner, L.
    Wong, Y. N.
    Yu, E.
    Alva, A.
    Crabb, S.
    Powles, T.
    Rosenberg, J.
    Baniel, J.
    Vaishampayan, U.
    Berthold, D.
    Ladoire, S.
    Hussain, S.
    Milowsky, M.
    Agarwal, N.
    Necchi, A.
    Pal, S.
    Recine, F.
    Bellmunt, J.
    Galsky, M.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S518 - S518
  • [7] Sarcopenia and Response to Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer
    Lyon, Timothy D.
    Frank, Igor
    Takahashi, Naoki
    Boorjian, Stephen A.
    Moynagh, Michael R.
    Shah, Paras H.
    Tarrell, Robert F.
    Cheville, John C.
    Viers, Boyd R.
    Tollefson, Matthew K.
    CLINICAL GENITOURINARY CANCER, 2019, 17 (03) : 216 - +
  • [8] Tolerability of neoadjuvant chemotherapy with gemcitabine plus cisplatin in elderly (older than age 65) patients (pts) with muscle-invasive urothelial cancer
    Niedersuess-Beke, D.
    Gruenberger, B.
    Puntus, T.
    Bauer, W.
    Lamche, M.
    Schramek, P.
    Meran, J. G.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (07)
  • [9] Multidisciplinary management and use of neoadjuvant cisplatin combination chemotherapy in patients with muscle-invasive urothelial bladder cancer
    Hoffman-Censits, Jean H.
    Lin, Jianqing
    Lallas, Costas D.
    Showalter, Timothy Norman
    Den, Robert Benjamin
    Doubet, Ellen
    Brown, Jillian
    Singh, Jaspreet
    Dicker, Adam
    Gomella, Leonard G.
    Kelly, William Kevin
    Trabulsi, Edouard John
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [10] Determinants of neoadjuvant chemotherapy for urothelial muscle-invasive bladder cancer: Does location matter?
    Monaghan, Thomas F.
    Robins, Dennis J.
    Suss, Nicholas R.
    Miller, Connelly D.
    Flores, Viktor X.
    Smith, Matthew T.
    Weiss, Jeffrey P.
    McNeil, Brian K.
    Winer, Andrew G.
    INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2021, 75 (08)
12345